{"entity":{"id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of mRNA-2808 in multiple myeloma, run by ModernaTX, Inc., now recruiting.","summary":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07116616 by ModernaTX, Inc., with 166 participants planned, started 2025-09-30 and due to reach its primary completion in 2030-06-17. Interventions recorded: mRNA-2808.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07116616","url":"https://clinicaltrials.gov/study/NCT07116616"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07116616","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"ModernaTX, Inc.","enrolled":166,"outcomes":[]},"route":"/trials/nct07116616/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}]}}